|
|
|
| Clinical Application of Treprostinil in Combination with Salmeterol and Ficasone in Patients with Chronic Obstructive Pulmonary Disease and Severe Pulmonary Hypertension |
| HU Xiaochun, LIU Shiwu, TENG Lifeng, et al |
| Hainan Provincial People's Hospital, Hainan Haikou 570311, China |
|
|
|
|
Abstract Objective: To explore the clinical effect of treprostinil in combination with salmeterol on patients with chronic obstructive pulmonary disease (COPD) and severe pulmonary hypertension (PAH). Methods: A total of 147 COPD patients with severe PAH admitted to our hospital from January 2018 to January 2021 were selected for the study. The random number table method was used for simple random grouping, and they were divided into two groups: study group and control group, with 77 cases in study group. In the control group, 70 cases were treated with Trepronil injection. The study group was combined with salmeterol and ticasone powder on this basis. Both groups were treated for 21 days. The clinical efficacy, pulmonary function parameters [1st second expiratory volume (FEV1) as a percentage of predicted value (FEV1%pred) and 1st second expiratory volume to expiratory spirometry ratio (FEV1/FVC)], plasma levels of nitric oxide (NO), endothelin (ET-1), soluble guanylate cyclase (cGMP), adenylate cyclase (cAMP), serum inflammatory factors [Apelin, tumour necrosis factor-α (TNF-α), hypersensitive C-reactive protein (hs-CRP)], and the occurrence of adverse reactions between the two groups were compared. Results: The total effective rates of the study group and the control group were 93.51% and 78.57% respectively (P＜0.05); the difference in FEV1/FVC and FEV1%pre, NO, ET-1, cGMP, cAMP, hs-CRP, TNF-αand Apelin before and after treatment in the study group was higher than the difference before and after treatment in the control group (P<0.05); there was no significant difference in adverse reactions between the two groups (P>0.05). Conclusion: Treprostinil in combination with salmeterol and ticassone has significant effects in the treatment of chronic obstructive pulmonary disease complicated with severe pulmonary hypertension. It has great advantages in improving lung function and reducing inflammation, and is suitable for popularization and application.
|
|
|
|
|
|
[1] 阚亚楠,钮美娥,耿敏,等.慢性阻塞性肺疾病患者延迟就医原因的质性研究[J].护理学杂志,2019,34(17):36~38.
[2] 王莹,陈亚红.慢性阻塞性肺疾病合并重度肺动脉高压的诊断与治疗[J].中国医师杂志,2019,21(10):1452~1455.
[3] Cave A, Pham A, Lindeman C,et al.Chronic obstructive pulmonary disease as a risk factor in primary care:a Canadian retrospective cohort study[J].Primary Care Respiratory Medicine,2021,31(1):37.
[4] 罗勤,柳志红.肺动脉高压靶向药物治疗原则与进展[J].中国循环杂志,2020,35(6),611~614.
[5] Chaouat A,Naeije R,Weitzenblum E.Pulmonary hypertension in COPD[J].Eur Respir,2008,32:1371~1385.
[6] Klinger J R.Treatment of pulmonary hypertension associated with COPD[J].Chest,2021,160(2):409~410.
[7] 谢焕章,贾力.肺动脉高压治疗药物研究进展[J].中国药理学与毒理学杂志,2019,33(10):62~63.
[8] 刘温娟,黄爱霞,鲁立文.慢性阻塞性肺疾病合并肺动脉高压炎性介质研究[J].临床军医杂志,2019,47(1):15~17,20.
[9] 俞洋,欧阳洋,杨晓龙.沙美特罗替卡松对慢性阻塞性肺疾病急性加重期肺功能,炎症应激及血气分析指标的影响[J].海军医学杂志,2020,172(1):104~106. |
|
|
|
2022, Vol. 28 
